Posts in category Long Ideas


QUALCOMM, Inc. (QCOM) Wins Over New Confidence from Christopher Rolland

Susquehanna’s Christopher Rolland boosts his price target on QCOM stock on back of $1 billion cost reduction initiative.

Twitter Inc Multi-Year Turnaround Only Just Beginning

BTIG’s Richard Greenfield praises the TWTR management’s team savvy efforts to realize a “far more engaged user base.”

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Charms a New Bull Who Says the Stock Is “Less Risky” After Cost-Cutting

Mizuho’s Irina Rivkind Koffler is leaving the sidelines on Teba and boosting her price target, now angling for 19% upside.

HTG Molecular Diagnostics Inc (HTGM) Gets a Price Target Jump from This Bull Following Second Consecutive Financial Outclass

Canaccord’s Mark Massaro is impressed that even after recent HTGM share volatility, the healthcare player still delivered an impressive robust fourth quarter turnout for 2017.

NXT-ID Inc (NXTD) Stock Can Reach $6: Brian Kinstlinger

Maxim’s Brian Kinstlinger: The recent capital raise is a significant positive event for NXTD.

Twitter Inc (TWTR) Attracts a New Vote of Confidence on Back of 2018 Upside

J.P. Morgan’s Doug Anmuth believes more advertisers are “re-engaging” with Twitter’s platform and sees exciting revenue gains coming next year.

Micron Technology, Inc. (MU) Draws a Confident Price Target Lift Ahead of Next Week’s Earnings Show

MKM’s Ruben Roy now sees 27% upside potential for Micron shares ahead of its FQ1 results, believing memory trends are looking mostly positive.

Did Galectin Therapeutics Inc (GALT) Really Fail Big in NASH? This Bull Says No as He Hikes Up the Price Target

H.C. Wainwright’s Ed Arce believes the market’s reaction is not on point, instead opting to recognize GALT’s NASH cirrhosis Phase 2b study as a “landmark,” clinically meaningful win.

SAGE Therapeutics Inc (SAGE) Wins Price Target Hike on Back of Encouraging MDD Data

Canaccord’s John Newman now sees almost 18% in upside potential for SAGE following a big clinical home run in major depressive disorder.

Show More